Physician profile
Goroh Okazaki
NPI 1578856217
$1,636.01
in general payments reported to CMS, 2019-2025
35 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $43.42 · 2022: $126 · 2023: $290 · 2024: $360 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $191.91 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Pfizer INC. | $121.80 | 2019-2025 | |
| Novo Nordisk INC | $105.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $96.90 | 2019-2023 | Belsomra |
| Lilly USA, LLC | $95.96 | 2019-2025 | Zepbound, Mounjaro |
| Inspire Medical Systems, INC. | $85.76 | 2024 | Inspire |
| Abbvie INC. | $72.28 | 2024-2025 | |
| Alkermes, INC. | $70.33 | 2023-2024 | Aristada, Lybalvi |
| Glaxosmithkline, LLC. | $65.85 | 2025 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $63.20 | 2019-2025 | |
| Boston Scientific Corporation | $62.53 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Hologic Sales and Service, LLC | $60.81 | 2022-2023 | Thinprep 2000 Processor, Aptima |
| Exact Sciences Corporation | $50.64 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $50.32 | 2023-2025 | Veozah |
| Dexcom, INC. | $47.46 | 2023-2025 | Dexcom G6 Transmitter |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $44.85 | 2022-2025 | Otezla, Repatha, Repatha |
| Teva Pharmaceuticals USA, INC. | $25.91 | 2024 | Austedo Xr |
| Aimmune Therapeutics, INC. | $24.57 | 2025 | Zenpep |
| Viiv Healthcare Company | $23.73 | 2023 | Dovato |
| Horizon Therapeutics Plc | $22.64 | 2023 | Krystexxa |
| Xeris Pharmaceuticals, INC. | $22.59 | 2025 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.91 | 2022 | |
| Medtronic, INC. | $20.73 | 2025 | Symplicity G3 |
| Actelion Pharmaceuticals US, INC. | $19.25 | 2025 | Uptravi, Opsumit |
| Lundbeck LLC | $19.09 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.56 | 2019 | |
| Sanofi Pasteur INC. | $17.40 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $17.28 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.31 | 2022 | |
| Shire North American Group INC | $14.57 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.26 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $13.69 | 2025 | Contrave |
| Hikma Pharmaceuticals USA | $13.58 | 2019 | |
| Mylan Specialty L.P. | $13.36 | 2019 | |
| Phadia US INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Goroh Okazaki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.